Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness,...
Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness,...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide...
Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager,...
Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the fourth quarter and full year...
In a case study, a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved an “almost complete recovery of osteoporosis” after one year of pelleted testosterone therapy and experienced...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in...
Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide...